- July 22, 2021: Information about increasing echinocandin- and pan-resistant cases in the United States added to Surveillance and Treatment and Management of Infections and Colonization. Combination antifungal therapy or investigational drugs may be needed for pan-resistant strains.
- July 19, 2021: Environmental Protection Agency (EPA) has created List P, a list of EPA-registered disinfectants effective against C. auris.
- May 11, 2021: Updated Tracking Candida auris to include historical and current U.S. interactive maps and downloadable datasets
- December 1, 2020: Added page for Fungal Diseases and COVID-19, including information on the spread of C. auris during the pandemic and invasive candidiasis in patients with COVID-19
Candida auris is an emerging fungus that presents a serious global health threat. CDC is concerned about C. auris for three main reasons:
- It is often multidrug-resistant, meaning that it is resistant to multiple antifungal drugs commonly used to treat Candida infections. Some strains are resistant to all three available classes of antifungals.
- It is difficult to identify with standard laboratory methods, and it can be misidentified in labs without specific technology. Misidentification may lead to inappropriate management.
- It has caused outbreaks in healthcare settings. For this reason, it is important to quickly identify C. auris in a hospitalized patient so that healthcare facilities can take special precautions to stop its spread.
CDC encourages all U.S. laboratory staff who identify C. auris to notify their state or local public health authorities and CDC at firstname.lastname@example.org.
Learn more about how CDC uses whole genome sequencing to detect outbreaks of C. auris in healthcare facilities.